Compare Boeing Co (BA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs Novo Nordisk A/S — how do they compare? Boeing Co trades at $233.65 (market cap $184.35B), while Novo Nordisk A/S trades at $46.03 (market cap $207.85B). The key difference: Boeing Co and Novo Nordisk A/S are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| BA | NVO | |
|---|---|---|
Market Cap | $184.35B | $207.85B |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $63.98 |
52-Week Low | $179.12 | $35.29 |
Enterprise Value | $210.23B | $222.55B |
Dividend Yield | 0.03% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.79, down 0.7% on the day, with a bullish technical signal supported by moving averages. The company reported revenue of $89.46B in 2025, swinging to a net income of $2.24B, and recent news highlights its strategic sale of non-core aviation technology units to Archer Aviation to sharpen focus on core aerospace and defense operations.
The outlook is positive with a consensus price target of $280.83, though high valuation ratios and volatile cash flows pose risks. Earnings momentum is mixed, with a recent Q2 2026 EPS miss, but analyst sentiment remains strongly bullish with 67% buy ratings.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
